Cargando…
Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications
BACKGROUND: New therapies are urgently needed in melanoma particularly in late-stage patients not responsive to immunotherapies and kinase inhibitors. METHODS: Drug screening, IC50 determinations as well as synergy assays were detected by the MTT assay. Apoptosis using Annexin V and 7AAD staining wa...
Autores principales: | Liu, Wei, Stachura, Paweł, Xu, Haifeng C., Umesh Ganesh, Nikkitha, Cox, Fiona, Wang, Ruifeng, Lang, Karl S., Gopalakrishnan, Jay, Häussinger, Dieter, Homey, Bernhard, Lang, Philipp A., Pandyra, Aleksandra A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035645/ https://www.ncbi.nlm.nih.gov/pubmed/32085796 http://dx.doi.org/10.1186/s13046-020-1539-7 |
Ejemplares similares
-
BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
por: Liu, Wei, et al.
Publicado: (2022) -
Active Targeted Nanoemulsions for Repurposing of Tegaserod in Alzheimer’s Disease Treatment
por: Séguy, Line, et al.
Publicado: (2021) -
Unleashing T cell anti-tumor immunity: new potential for 5-Nonloxytryptamine as an agent mediating MHC-I upregulation in tumors
por: Stachura, Paweł, et al.
Publicado: (2023) -
Tegaserod for the Treatment of Irritable Bowel Syndrome
por: Madia, Valentina Noemi, et al.
Publicado: (2020) -
Comments on Tegaserod Trial on Irritable Bowel Syndrome
por: Jung, Hye-Kyung
Publicado: (2010)